Page last updated: 2024-08-23

brimonidine tartrate and Rosacea

brimonidine tartrate has been researched along with Rosacea in 63 studies

Research

Studies (63)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	51 (80.95)	24.3611
2020's	12 (19.05)	2.80

Authors

Authors	Studies
Agamia, N; El-Ariny, A; El-Nagdy, S	1
Coto-Segura, P; García García, B; Mir-Bonafé, M; Pérez González, LA	1
Chen, DW; Chen, QQ; Fu, J; Li, J; Li, X; Ni, RR; Song, GJ; Song, ZQ; Tang, JY; Wan, M; Zhang, MW	1
Bernhard, D; Clanner-Engelshofen, BM; Dargatz, S; Flaig, MJ; Gieler, U; Kinberger, M; Klövekorn, W; Kuna, AC; Läuchli, S; Lehmann, P; Nast, A; Pleyer, U; Reinholz, M; Schaller, M; Schöfer, H; Schwennesen, T; Steinhoff, M; Werner, RN; Zierhut, M	1
Ahramiyanpour, N; Amani, M; Hosseini, SA; Nezhad, NZ; Saki, N; Shafiei, M; Shahpar, A	1
Abdelhameed, SS; El-Domyati, M; Medhat, W; Nasif, G; Rezk, AF	1
Gold, MH; Ivanic, MG; Javadi, SS; Norden, A; Oulee, A; Wu, JJ	1
Dahlin, J; Sukakul, T; Svedman, C	1
Rusina, T; Snarskaya, E	1
Kang, CN; Shah, M; Tan, J	1
Cline, A; Gomolin, T; Pereira, F	1
Chong, AH; Maor, D	1
Jeong, SW; Jo, H; Kim, J; Kim, M; Park, HJ; Woo, YR	1
Lee, CN; Lee, JY	1
Bhatt, K; Dall'Oglio, F; Lacarrubba, F; Luppino, I; Micali, G; Verzì, AE	1
Gold, LS; Gooderham, M; Johnson, S; Kerrouche, N; Lain, E; Lynde, C; Papp, K	1
Cline, A; Feldman, SR; McGregor, SP	1
Gil, D; Hsia, E; Tian, M	1
Giam, YC; Kok, WL; Oon, HH	1
Bertino, B; Blanchet-Réthoré, S; Bogouch, A; Bourdès, V; Dugaret, AS; Gamboa, B; Méhul, B; Nonne, C; Petit, L; Piwnica, D; Reynier, P; Roquet, M; Thibaut de Ménonville, S; Vial, E; Voegel, JJ; Zugaj, D	1
Arents, BWM; Carter, B; Charland, L; Fedorowicz, Z; Tan, J; van der Linden, MMD; van Zuuren, EJ	1
Alegre, M; Alonso-Usero, V; Boixeda, P; Del Pozo-Losada, J; Domínguez-Silva, J; Fernández-Herrera, J; García-Navarro, X; Jiménez, N; Llamas, M; Nadal, C; Querol, I; Salgüero, I; Salleras, M; Schaller, M; Soto de Delás, J	1
Cline, A; Feldman, SR; Okwundu, N	1
Fowler, J; Jackson, M; Jarratt, M; Jones, T; Leoni, M; Meadows, K; Moore, A; Rudisill, D; Steinhoff, M	1
Del Rosso, JQ	1
Kempers, S; Leoni, M; Liu, H; Moore, A; Murakawa, G; Swinyer, L; Tauscher, A; Weiss, J	1
Levitt, JO; Routt, ET	1
Benkali, K; Bouer, R; Fernando, A; Graeber, M; Leoni, M; Rony, F; Wagner, N	1
Berson, D; Del Rosso, JQ; Eichenfield, LF; Gallo, R; Stein-Gold, L; Tanghetti, E; Thiboutot, D; Webster, G; Zaenglein, A	1
Ilkovitch, D; Pomerantz, RG	1
Fowler, J; Jackson, JM; Jarratt, M; Jones, T; Leoni, M; Meadows, K; Moore, A; Rudisill, D; Steinhoff, M	1
Kalowitz, A; Markowitz, O; Meekings, A; Siripunvarapon, AH; Urban, J	1
Fowler, J; Jackson, JM; Jarratt, M; Jones, T; Leoni, M; Meadows, K; Tan, J	1
Moore, AY; Tong, LX	1
Fowler, J	1
Hougeir, FG	1
Feldman, SR; Moustafa, FA; Sandoval, LF	1
Belasco, KT; Cadena, MJ; Friedrichs, A; Hinek, A; Hong, HC; Hougier, F; Jackson, JM; Johnson, SM; Kerdel, FA; Palceski, D; Tanghetti, EA	1
Kobayashi, TT; Werner, K	1
Carter, B; Charland, L; Fedorowicz, Z; van der Linden, MM; van Zuuren, EJ	1
Aires, D; Fischer, R; Gillihan, R; Nguyen, T; Rajpara, A	1
Leoni, M; Tan, J	1
Draelos, ZD; Gold, LM	1
Bewley, AP; Hofmann, MA; Homey, B; Kerrouche, N; Layton, AM; Lehmann, P; Ma, YM; Nohlgård, C; Sarwer, DB; Schaller, M	1
Van Genechten, D	1
Schauber, J; Schmelz, M; Steinhoff, M	1
Gerber, PA	1
Lim, ZV; Oon, HH	1
Cookson, H; McFadden, J; White, IR; White, J	1
Bangsgaard, N; Fischer, LA; Zachariae, C	1
Lim, S; Lowe, E	1
Helfrich, YR; Maier, LM	1
Keri, J	1
Fowler, JF	1
Detmar, M; Di Nardo, A; Docherty, JR; Holmes, A; Lorton, D; Schäfer, G; Steinhoff, M	1
Gonser, L; Schaller, M	1
Hofmann, MA; Kokolakis, G	1
Fowler, J; Jarratt, M; Leoni, M; Liu, Y; Meadows, K; Moore, A; Pollack, A; Steinhoff, M	1
Fallen, RS; Gooderham, M	1

Reviews

17 review(s) available for brimonidine tartrate and Rosacea

Article	Year
Efficacy and safety of topical brimonidine in dermatology: A review article. Dermatologic therapy, 2022, Volume: 35, Issue:11 Topics: Brimonidine Tartrate; Dermatology; Erythema; Humans; Rosacea; Treatment Outcome	2022
Neurogenic Rosacea Treatment: A Literature Review. Journal of drugs in dermatology : JDD, 2023, Jun-01, Volume: 22, Issue:6 Topics: Anti-Bacterial Agents; Brimonidine Tartrate; Erythema; Humans; Metronidazole; Rosacea	2023
Treatment of rosacea during pregnancy. Dermatology online journal, 2021, Jul-15, Volume: 27, Issue:7 Topics: Adult; Algorithms; Animals; Anti-Bacterial Agents; Azithromycin; Brimonidine Tartrate; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Female; Humans; Isotretinoin; Ivermectin; Metronidazole; Mice; Minocycline; Phototherapy; Pregnancy; Pregnancy Complications; Randomized Controlled Trials as Topic; Rosacea; Tetracyclines; Treatment Outcome	2021
Medical Management of Facial Redness in Rosacea. Dermatologic clinics, 2018, Volume: 36, Issue:2 Topics: Administration, Cutaneous; Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Calcineurin Inhibitors; Erythema; Face; Humans; Off-Label Use; Oxymetazoline; Retinoids; Rosacea; Tetracyclines	2018
Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. The British journal of dermatology, 2019, Volume: 181, Issue:1 Topics: Administration, Cutaneous; Administration, Oral; Anti-Bacterial Agents; Brimonidine Tartrate; Combined Modality Therapy; Dermatologic Agents; Dermatology; Drug Therapy, Combination; Evidence-Based Medicine; Facial Dermatoses; Humans; Intense Pulsed Light Therapy; Low-Level Light Therapy; Oxymetazoline; Randomized Controlled Trials as Topic; Rosacea; Severity of Illness Index; Treatment Outcome	2019
Rosacea First-choice treatments. Prescrire international, 2017, Volume: 26, Issue:182 Topics: Administration, Cutaneous; Administration, Oral; Adrenergic alpha-2 Receptor Agonists; Anti-Bacterial Agents; Antiparasitic Agents; Azithromycin; Brimonidine Tartrate; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Humans; Ivermectin; Metronidazole; Rosacea	2017
Spanish Consensus Document on the Treatment Algorithm for Rosacea. Actas dermo-sifiliograficas, 2019, Volume: 110, Issue:7 Topics: Algorithms; Anti-Bacterial Agents; Brimonidine Tartrate; Consensus; Delphi Technique; Doxycycline; Humans; Laser Therapy; Metronidazole; Practice Guidelines as Topic; Quality of Life; Rosacea	2019
Difference in vasoconstrictors: oxymetazoline vs. brimonidine. The Journal of dermatological treatment, 2021, Volume: 32, Issue:2 Topics: Administration, Topical; Brimonidine Tartrate; Clinical Trials as Topic; Dermatitis; Erythema; Humans; Oxymetazoline; Rosacea; Treatment Outcome; Vasoconstrictor Agents	2021
Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea. Expert review of clinical pharmacology, 2014, Volume: 7, Issue:5 Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Erythema; Humans; Quality of Life; Quinoxalines; Rosacea; Treatment Outcome	2014
Rosacea: new and emerging treatments. Drugs, 2014, Volume: 74, Issue:13 Topics: Administration, Cutaneous; Brimonidine Tartrate; Dermatologic Agents; Drug Design; Humans; Ivermectin; Oxymetazoline; Quality of Life; Quinoxalines; Randomized Controlled Trials as Topic; Rosacea	2014
Brimonidine for erythema caused by rosacea. Drug and therapeutics bulletin, 2014, Volume: 52, Issue:12 Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Contraindications; Drug Costs; Drug Interactions; Erythema; Humans; Quinoxalines; Rosacea	2014
Interventions for rosacea. The Cochrane database of systematic reviews, 2015, Apr-28, Issue:4 Topics: Anti-Infective Agents; Brimonidine Tartrate; Cyclosporine; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Female; Humans; Ivermectin; Male; Metronidazole; Middle Aged; Ophthalmic Solutions; Quinoxalines; Randomized Controlled Trials as Topic; Rosacea; Tetracycline	2015
New and Emerging Treatments for Rosacea. American journal of clinical dermatology, 2015, Volume: 16, Issue:6 Topics: Administration, Topical; Brimonidine Tartrate; Clinical Trials, Phase III as Topic; Dermatologic Agents; Dicarboxylic Acids; Drug Approval; Female; Follow-Up Studies; Forecasting; Humans; Ivermectin; Male; Oxymetazoline; Patient Satisfaction; Rosacea; Severity of Illness Index; Treatment Outcome; United States; United States Food and Drug Administration	2015
Facial Erythema of Rosacea - Aetiology, Different Pathophysiologies and Treatment Options. Acta dermato-venereologica, 2016, Jun-15, Volume: 96, Issue:5 Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Antihypertensive Agents; Brimonidine Tartrate; Erythema; Humans; Rosacea	2016
Topical and oral therapeutic approach to rosacea. Seminars in cutaneous medicine and surgery, 2016, Volume: 35, Issue:2 Topics: Administration, Cutaneous; Administration, Oral; Brimonidine Tartrate; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Evidence-Based Medicine; Humans; Ivermectin; Metronidazole; Rosacea; Treatment Outcome	2016
What's new in acne and rosacea? Seminars in cutaneous medicine and surgery, 2016, Volume: 35, Issue:2 Topics: Acne Vulgaris; Brimonidine Tartrate; Dapsone; Dermatologic Agents; Dermatology; Gels; Humans; Isotretinoin; Ivermectin; Rosacea; Skin Cream; Treatment Outcome	2016
Multidisciplinary Consideration of Potential Pathophysiologic Mechanisms of Paradoxical Erythema with Topical Brimonidine Therapy. Advances in therapy, 2016, Volume: 33, Issue:11 Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Disease Management; Humans; Interdisciplinary Communication; Rosacea	2016

Trials

12 trial(s) available for brimonidine tartrate and Rosacea

Article	Year
Carvedilol ameliorates persistent erythema of erythematotelangiectatic rosacea by regulating the status of anxiety/depression. The Journal of dermatology, 2022, Volume: 49, Issue:11 Topics: Adult; Anxiety; Brimonidine Tartrate; Carvedilol; Depression; Erythema; Humans; Rosacea	2022
Treatment of erythemato-telangiectatic rosacea with brimonidine alone or combined with vascular laser based on preliminary instrumental evaluation of the vascular component. Lasers in medical science, 2018, Volume: 33, Issue:6 Topics: Administration, Cutaneous; Adult; Brimonidine Tartrate; Combined Modality Therapy; Dermoscopy; Erythema; Female; Gels; Humans; Lasers, Solid-State; Male; Middle Aged; Photography; Rosacea; Telangiectasis; Treatment Outcome; Young Adult	2018
Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study. Journal of drugs in dermatology : JDD, 2017, Sep-01, Volume: 16, Issue:9 Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Dermatologic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gels; Humans; Ivermectin; Male; Middle Aged; Patient Satisfaction; Rosacea; Skin Cream; Treatment Outcome; Young Adult	2017
Brimonidine displays anti-inflammatory properties in the skin through the modulation of the vascular barrier function. Experimental dermatology, 2018, Volume: 27, Issue:12 Topics: Administration, Cutaneous; Adolescent; Adult; Animals; Anti-Inflammatory Agents; Brimonidine Tartrate; Cell Movement; Dermatitis; Endothelial Cells; Erythema; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Male; Mice; Middle Aged; Neutrophils; Proteome; Rosacea; Skin; Ultraviolet Rays; Vasodilation; Young Adult	2018
Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. Journal of drugs in dermatology : JDD, 2013, Jun-01, Volume: 12, Issue:6 Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Dermatologic Agents; Double-Blind Method; Facial Dermatoses; Female; Follow-Up Studies; Gels; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult	2013
Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:1 Topics: Administration, Cutaneous; Administration, Topical; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Erythema; Face; Female; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Social Behavior; Treatment Outcome; Young Adult	2014
Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea. The British journal of dermatology, 2014, Volume: 171, Issue:1 Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Adult; Area Under Curve; Biological Availability; Brimonidine Tartrate; Drug Administration Schedule; Facial Dermatoses; Female; Gels; Humans; Male; Ophthalmic Solutions; Quinoxalines; Rosacea	2014
Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:6 Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Dermatologic Agents; Double-Blind Method; Erythema; Female; Gels; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult	2014
Treatment of facial erythema in patients with rosacea with topical brimonidine tartrate: correlation of patient satisfaction with standard clinical endpoints of improvement of facial erythema. Journal of the European Academy of Dermatology and Venereology : JEADV, 2015, Volume: 29, Issue:3 Topics: Adult; Brimonidine Tartrate; Double-Blind Method; Erythema; Face; Female; Humans; Male; Middle Aged; Patient Satisfaction; Rosacea	2015
Erythema of Rosacea: Validation of Patient's Self-Assessment Grading Scale. Journal of drugs in dermatology : JDD, 2015, Volume: 14, Issue:8 Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Brimonidine Tartrate; Diagnostic Self Evaluation; Double-Blind Method; Erythema; Facial Dermatoses; Female; Gels; Humans; Male; Reproducibility of Results; Rosacea; Severity of Illness Index; Young Adult	2015
Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. Journal of the European Academy of Dermatology and Venereology : JEADV, 2015, Volume: 29, Issue:12 Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Brimonidine Tartrate; Erythema; Facial Dermatoses; Female; Gels; Humans; Male; Middle Aged; Patient Satisfaction; Rosacea; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Young Adult	2015
Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. The British journal of dermatology, 2012, Volume: 166, Issue:3 Topics: Administration, Cutaneous; Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Brimonidine Tartrate; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Facial Dermatoses; Female; Gels; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Treatment Outcome; Young Adult	2012

Other Studies

34 other study(ies) available for brimonidine tartrate and Rosacea

Article	Year
A split face comparative study using a novel triple combination therapy for the treatment of persistent post acne erythema. Dermatologic therapy, 2022, Volume: 35, Issue:4 Topics: Acne Vulgaris; Administration, Topical; Brimonidine Tartrate; Drug Therapy, Combination; Erythema; Humans; Oxymetazoline; Rosacea; Treatment Outcome	2022
Rapid and sustained improvement of dupilumab-associated head and neck erythema with topical brimonidine. Dermatologic therapy, 2022, Volume: 35, Issue:6 Topics: Antibodies, Monoclonal, Humanized; Brimonidine Tartrate; Erythema; Humans; Rosacea	2022
S2k guideline: Rosacea. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2022, Volume: 20, Issue:8 Topics: Brimonidine Tartrate; Dermatologic Agents; Erythema; Humans; Ivermectin; Metronidazole; Rosacea	2022
Topical brimonidine for the management of facial erythema in rosacea: a histological, histometric, and immunohistochemical study. International journal of dermatology, 2023, Volume: 62, Issue:7 Topics: Administration, Cutaneous; Brimonidine Tartrate; Erythema; Humans; Ophthalmic Solutions; Rosacea; Treatment Outcome	2023
Primum non nocere; the importance of evaluating the effect of treatment and considering side effects. Contact dermatitis, 2021, Volume: 84, Issue:2 Topics: Anti-Inflammatory Agents; Brimonidine Tartrate; Budesonide; Dermatologic Agents; Diagnosis, Differential; Erythema; Facial Dermatoses; Humans; Hydrocortisone; Male; Middle Aged; Patch Tests; Rosacea	2021
Erythematotelangiectatic rosacea: The combination of 0.5% brimonidine tartrate gel and broadband pulse light therapy to reverse its effects. Journal of cosmetic dermatology, 2021, Volume: 20, Issue:7 Topics: Brimonidine Tartrate; Dermatologic Agents; Erythema; Humans; Phototherapy; Rosacea	2021
Rosacea: An Update in Diagnosis, Classification and Management. Skin therapy letter, 2021, Volume: 26, Issue:4 Topics: Brimonidine Tartrate; Dermatologic Agents; Doxycycline; Humans; Metronidazole; Rosacea	2021
Rosacea. Australian family physician, 2017, Volume: 46, Issue:5 Topics: Anti-Bacterial Agents; Brimonidine Tartrate; Diagnosis, Differential; Doxycycline; Humans; Isotretinoin; Ivermectin; Laser Therapy; Metronidazole; Rosacea	2017
Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel. Experimental dermatology, 2017, Volume: 26, Issue:11 Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Animals; Antimicrobial Cationic Peptides; Brimonidine Tartrate; Cathelicidins; Cell Movement; Disease Models, Animal; Enzyme Induction; Enzymes; Female; Gels; Mast Cells; Mice; RNA, Messenger; Rosacea	2017
Severe erythematotelangiectatic rosacea with cold wave-induced epidermal necrosis treated with carvedilol combined with brimonidine gel. Dermatologic therapy, 2017, Volume: 30, Issue:4 Topics: Administration, Cutaneous; Brimonidine Tartrate; Carbazoles; Carvedilol; Cold Temperature; Dermatologic Agents; Female; Gels; Humans; Middle Aged; Necrosis; Propanolamines; Rosacea; Severity of Illness Index; Skin Diseases	2017
Reduction in ultraviolet B light-induced erythema by oxymetazoline and brimonidine is mediated by different α-adrenoceptors. Experimental dermatology, 2018, Volume: 27, Issue:7 Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Brimonidine Tartrate; Calcium; Disease Models, Animal; Erythema; HEK293 Cells; Humans; Male; Mice; Mice, Hairless; Oxymetazoline; Prazosin; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Rosacea; Ultraviolet Rays; Vasoconstriction; Yohimbine	2018
A case report of granulomatous rosacea of the face. Singapore medical journal, 2018, Volume: 59, Issue:4 Topics: Administration, Oral; Anti-Bacterial Agents; Brimonidine Tartrate; Diagnosis, Differential; Doxycycline; Face; Female; Humans; Inflammation; Middle Aged; Rosacea; Singapore; Steroids; Treatment Outcome	2018
INN Common stem: -onidine. Prescrire international, 2017, Volume: 26, Issue:181 Topics: Adrenergic alpha-2 Receptor Agonists; Antimalarials; Brimonidine Tartrate; Cinchona Alkaloids; Clonidine; Humans; Hypertension; Imidazoles; Ocular Hypertension; Rilmenidine; Rosacea; Terminology as Topic	2017
Brimonidine gel (Mirvaso) for rosacea. The Medical letter on drugs and therapeutics, 2013, Oct-14, Volume: 55, Issue:1427 Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Drug Approval; Gels; Humans; Quinoxalines; Randomized Controlled Trials as Topic; Rosacea; Treatment Outcome; United States; United States Food and Drug Administration	2013
Management of facial erythema of rosacea: what is the role of topical α-adrenergic receptor agonist therapy? Journal of the American Academy of Dermatology, 2013, Volume: 69, Issue:6 Suppl 1 Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Brimonidine Tartrate; Erythema; Humans; Oxymetazoline; Quinoxalines; Rosacea; Sympathetic Nervous System; Vasodilation	2013
Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%. Journal of the American Academy of Dermatology, 2014, Volume: 70, Issue:2 Topics: Administration, Cutaneous; Adult; Brimonidine Tartrate; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Female; Follow-Up Studies; Gels; Humans; Pain; Quinoxalines; Recurrence; Risk Assessment; Rosacea; Sampling Studies; Severity of Illness Index	2014
Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis, 2014, Volume: 93, Issue:3 Topics: Administration, Cutaneous; Administration, Oral; Adrenergic alpha-2 Receptor Agonists; Anti-Infective Agents; Brimonidine Tartrate; Consensus; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Erythema; Humans; Metronidazole; Quinoxalines; Rosacea; Severity of Illness Index; Societies, Medical	2014
Brimonidine effective but may lead to significant rebound erythema. Journal of the American Academy of Dermatology, 2014, Volume: 70, Issue:5 Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Brimonidine Tartrate; Erythema; Female; Humans; Quinoxalines; Rosacea; Vasoconstriction	2014
Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment. Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:7 Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Adult; Brimonidine Tartrate; Female; Gels; Humans; Quinoxalines; Rosacea; Severity of Illness Index; Tomography, Optical Coherence; Treatment Outcome	2014
New agents for the treatment of erythematotelangiectatic rosacea. Cutis, 2014, Volume: 94, Issue:1 Topics: Brimonidine Tartrate; Clinical Trials as Topic; Dermatologic Agents; Gels; Humans; Oxymetazoline; Quinoxalines; Rosacea; Treatment Outcome	2014
[Erythema of rosacea: a new and effective treatment]. Annales de dermatologie et de venereologie, 2014, Volume: 141 Suppl 2 Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Erythema; Female; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Treatment Outcome	2014
Optimizing the use of topical brimonidine in rosacea management: panel recommendations. Journal of drugs in dermatology : JDD, 2015, Volume: 14, Issue:1 Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Dermatologic Agents; Gels; Humans; Quinoxalines; Rosacea; Treatment Outcome	2015
Dermatitis medicamentosa: severe rebound erythema secondary to topical brimonidine in rosacea. Dermatology online journal, 2015, Jan-01, Volume: 21, Issue:3 Topics: Adult; Brimonidine Tartrate; Dermatologic Agents; Drug Eruptions; Erythema; Female; Humans; Rosacea	2015
Erythema in Skin Adjacent to Area of Long-term Brimonidine Treatment for Rosacea: A Novel Adverse Reaction. JAMA dermatology, 2015, Volume: 151, Issue:10 Topics: Brimonidine Tartrate; Dermatologic Agents; Drug Eruptions; Erythema; Female; Humans; Middle Aged; Rosacea; Time Factors	2015
[Brimonidine (Mirvaso), dermal use]. Journal de pharmacie de Belgique, 2015, Issue:2 Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Humans; Rosacea	2015
Topical brimonidine tartrate 0·33% gel effectively reduces the post-treatment erythema of daylight-activated photodynamic therapy. The British journal of dermatology, 2016, Volume: 174, Issue:6 Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Adult; Brimonidine Tartrate; Drug Eruptions; Erythema; Facial Dermatoses; Gels; Humans; Male; Photochemotherapy; Rosacea; Sunlight	2016
Rosacea or photodamaged skin? Use of brimonidine gel in differentiating erythema in the two conditions. The Australasian journal of dermatology, 2017, Volume: 58, Issue:1 Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Brimonidine Tartrate; Diagnosis, Differential; Gels; Humans; Male; Rosacea; Skin Aging	2017
Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema. Contact dermatitis, 2015, Volume: 73, Issue:6 Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Dermatitis, Allergic Contact; Dermatologic Agents; Facial Dermatoses; Female; Gels; Humans; Rosacea; Young Adult	2015
Sensitization to and allergic contact dermatitis caused by Mirvaso(®) (brimonidine tartrate) for treatment of rosacea - 2 cases. Contact dermatitis, 2016, Volume: 74, Issue:6 Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Dermatitis, Allergic Contact; Facial Dermatoses; Humans; Male; Middle Aged; Rosacea	2016
Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea. Journal of drugs in dermatology : JDD, 2016, Jun-01, Volume: 15, Issue:6 Topics: Administration, Cutaneous; Adult; Brimonidine Tartrate; Drug Administration Schedule; Erythema; Female; Gels; Humans; Rosacea; Treatment Outcome	2016
Facial Dermatitis and Rosacea. Seminars in cutaneous medicine and surgery, 2016, Volume: 35, Issue:6 Suppl Topics: Adrenal Cortex Hormones; Adrenergic alpha-2 Receptor Agonists; Antimicrobial Cationic Peptides; Antiparasitic Agents; Brimonidine Tartrate; Cathelicidins; Dermatitis; Dermatologic Agents; Dicarboxylic Acids; Facial Dermatoses; Humans; Ivermectin; Rosacea	2016
A Tailored Approach to the Treatment of a Patient with a Severe Dynamic Manifestation of Rosacea: A Case Report. Drugs in R&D, 2016, Volume: 16, Issue:3 Topics: Administration, Topical; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Brimonidine Tartrate; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Isotretinoin; Metronidazole; Prednisolone; Rosacea	2016
A case report of combination treatment with potassium-titanyl phosphate laser and brimonidine topical gel in erythematotelangiectatic rosacea. Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology, 2017, Volume: 19, Issue:4 Topics: Administration, Cutaneous; Adult; Brimonidine Tartrate; Combined Modality Therapy; Dermatologic Agents; Humans; Lasers, Solid-State; Male; Phosphates; Potassium; Rosacea; Treatment Outcome	2017
Rosacea: update on management and emerging therapies. Skin therapy letter, 2012, Volume: 17, Issue:10 Topics: Administration, Cutaneous; Adrenergic Agents; Anti-Infective Agents; Antiparasitic Agents; Brimonidine Tartrate; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Female; Humans; Ivermectin; Male; Metronidazole; Oxymetazoline; Quality of Life; Quinoxalines; Randomized Controlled Trials as Topic; Rosacea; Sulfacetamide; Treatment Outcome	2012